Diamyd Medical AB (publ) (DMN.F)

0.8600 +0.0040 (+0.47%) At close: 08:15AM CEST

Diamyd Medical AB (publ)

Kungsgatan 29
Stockholm 111 56
Sweden
46 86 61 00 26
https://www.diamyd.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ulf Hannelius MBA, Ph.D.	CEO & President	3.01M	N/A	1975
Ms. Anna Styrud BSc	Chief Financial Officer	N/A	N/A	1961
Ms. Martina Widman	Chief Operating Officer	N/A	N/A	1981
Mr. Anton Lindqvist	Chief Scientific Officer	N/A	N/A	1980
Eva Karlstrom	Chief Regulatory Affairs Officer	N/A	N/A	1964
Mr. Christoph Nowak M.D., Ph.D.	Chief Medical & Business Officer	N/A	N/A	1986
Maja Johansson	Chief Operating Officer of Manufacturing Site	N/A	N/A	1962

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.

Corporate governance

Diamyd Medical AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.